October 8, 2020 — Galaxy Medical, a developer of pulsed electric field (PEF) technology for the treatment of cardiac arrhythmias, announced the first patients in the ECLIPSE-AF study were successfully treated with the proprietary Centauri System by Dr. Ante Anić in Split, Croatia. This multicenter trial is designed to assess the safety and efficacy of the Centauri System and is intended to support European CE-mark clearance.
The Centauri System is uniquely designed as an open energy platform with proprietary interface hardware and waveform control algorithms, which enable electrophysiologists to continue with the established point-by-point clinical workflow used in the majority of cardiac electrophysiology (EP) lab ablation procedures worldwide. Centauri offers the enhanced safety and efficacy features of PEF energy without the typical learning curve and workflow adjustments associated with new technologies.
Key features of the Centauri System include:
• Plug and play with all cardiac mapping and navigation systems.
• No compromise compatibility with market-released focal and contact force sensing catheters.
• Physician choice of dose setting when treating variable tissue thickness.
• Proprietary technology that completely eliminates microbubbles during PEF delivery.
• Automated voltage control to prevent overdosing or underdosing.
"The Galaxy Medical Centauri System operated seamlessly within my atrial fibrillation ablation clinical workflow," said Dr. Ante Anić, EP lab director at University Hospital Split and the Primary Investigator of the ECLIPSE-AF study. "Pulsed Electric Field energy is the future of EP and Centauri allowed me to deliver it with a standard focal ablation technique to patients under conscious sedation, and without compromising on the ablation catheter, contact force feedback, or cardiac mapping system."
PEF technology utilizes high voltage, high frequency bursts of electrosurgical energy to ablate tissue. In comparison to radiofrequency and cryoablation procedures, PEF has the potential to improve the safety of cardiac ablation by reducing the unintentional conductive heating or cooling of extracardiac structures including the esophagus, phrenic nerve, and airway. Efficacy may be enhanced with the creation of full-thickness, transmural lesions where the therapeutic dose of PEF energy is limited to the myocardium.
"In developing the Centauri System, our three main priorities are safety, interoperability, and efficacy. With the complete elimination of microbubbles, which may cause cerebral or coronary air emboli, we have addressed the primary safety concern with PEF technology in the heart," said Jonathan Waldstreicher, M.D., CEO of Galaxy Medical. "On interoperability, we integrate into today's EP lab with the tools that electrophysiologists have come to depend on to deliver safe and effective patient-centered ablation procedures tailored to each patient's unique anatomy, which will lead to more rapid uptake of this technology. And on efficacy, our research has consistently demonstrated that PEF with focal catheters yields predictable and transmural lesions as opposed to inconsistent ablation depth and intermittent electrical stunning associated with multipolar catheters with variable contact. We look forward to completing enrollment of the ECLIPSE-AF study and sharing the clinical experience in the near future."
As part of the ECLIPSE-AF study, patients will be assessed and followed with extensive safety and efficacy procedures including acute demonstration of entrance and exit block, monitoring of acute ST-segment changes, assessment of microbubbles on intracardiac echocardiography, assessment of pulmonary vein anatomy, three-month electrophysiologic remapping to confirm durability of pulmonary vein isolation, Holter monitoring at long term follow-up, cerebral MRI and upper GI endoscopy.
The Centauri System is an investigational device and not approved for commercial use.
Galaxy Medical is a privately held medical device company based in San Carlos, Calif., that is dedicated to developing therapies to treating patients with cardiac arrhythmias. Formed by Apple Tree Partners, a healthcare-focused venture capital firm based in New York, Galaxy is building a portfolio of technologies to address the needs of cardiac electrophysiologists.
PEF is also referred to as electroporation ablation, because the application of the field causes pores to develop in the cell walls, leading to cell death.
For more information: www.galaxymed.com
Related Pulse Electric Field Ablation Content:
Boston Scientific Invests in Pulsed Field Ablation Technology To Improve Atrial Fibrillation Therapy
Pulsed AF Trial Shows Pulsed Field Ablation May be Safer Than Traditional RF Ablations
Medtronic FDA Trial Evaluates Pulsed Electric Fields to Treat Atrial Fibrillation
October 30, 2024 
